Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Development of nomogram to non-steroidal antiandrogen sequential alternation in prostate cancer for predictive model.

Kamiya N, Suzuki H, Nishimura K, Fujii M, Okegawa T, Matsuda T, Morita T, Takihana Y, Ozono S, Namiki M, Matsubara A, Ichikawa T, Miki T.

Jpn J Clin Oncol. 2014 Mar;44(3):263-9. doi: 10.1093/jjco/hyt230. Epub 2014 Feb 9.

PMID:
24516203
2.

The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.

Soga N, Hori Y, Ogura Y, Hayashi N, Sugimura Y.

Jpn J Clin Oncol. 2012 Jun;42(6):534-40. doi: 10.1093/jjco/hys037. Epub 2012 Mar 20.

PMID:
22438406
3.

Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.

Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T; Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group..

J Urol. 2008 Sep;180(3):921-7. doi: 10.1016/j.juro.2008.05.045. Epub 2008 Jul 17.

PMID:
18635218
4.

Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.

Kobayashi M, Nukui A, Suzuki K, Kurokawa S, Morita T.

Int J Clin Oncol. 2011 Dec;16(6):630-6. doi: 10.1007/s10147-011-0232-4. Epub 2011 Apr 23.

PMID:
21512893
5.

Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.

Soga N, Arima K, Sugimura Y.

Jpn J Clin Oncol. 2008 Sep;38(9):617-22. doi: 10.1093/jjco/hyn071. Epub 2008 Aug 12.

PMID:
18697759
6.

Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.

D'Amico AV, Chen MH, Renshaw AA, Loffredo B, Kantoff PW.

J Clin Oncol. 2008 Jun 20;26(18):2979-83. doi: 10.1200/JCO.2007.15.9699.

PMID:
18565884
8.

Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy.

Okihara K, Ukimura O, Kanemitsu N, Mizutani Y, Kawauchi A, Miki T; Kyoto Prefectural University of Medicine Prostate Cancer Research Group..

Int J Urol. 2007 Feb;14(2):128-32. Erratum in: Int J Urol. 2007 Apr;14(4):373.

9.

Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience.

Okegawa T, Nutahara K, Higashihara E.

Int J Urol. 2010 Nov;17(11):950-5. doi: 10.1111/j.1442-2042.2010.02620.x.

10.

Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer.

Svatek R, Karakiewicz PI, Shulman M, Karam J, Perrotte P, Benaim E.

Eur Urol. 2006 Apr;49(4):666-74. Epub 2006 Jan 6.

PMID:
16423446
11.
12.

Comparison of goserelin and leuprolide in combined androgen blockade therapy.

Sarosdy MF, Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Vogelzang NJ, Chodak GW, Klein EA, Schellenger JJ, Kolvenbag GJ.

Urology. 1998 Jul;52(1):82-8.

PMID:
9671875
13.

Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?

Labrie F, Candas B, Gomez JL, Cusan L.

Urology. 2002 Jul;60(1):115-9.

PMID:
12100935
14.

Antiandrogen withdrawal in the treatment of hormone-relapsed prostate cancer: single institutional experience.

Caldiroli M, Cova V, Lovisolo JA, Reali L, Bono AV.

Eur Urol. 2001 Jan;39 Suppl 2:6-10.

PMID:
11223689
17.

Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.

Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H.

J Urol. 2004 Feb;171(2 Pt 1):679-83.

PMID:
14713785
18.

Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.

Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Kishikawa H, Ichikawa Y.

Int J Urol. 2007 Mar;14(3):264-7.

19.

External validation of preoperative nomograms predicting biochemical recurrence after radical prostatectomy.

Tanaka A, Ohori M, Paul L, Yu C, Kattan MW, Ohno Y, Tachibana M.

Jpn J Clin Oncol. 2013 Dec;43(12):1255-60. doi: 10.1093/jjco/hyt154. Epub 2013 Oct 21.

PMID:
24146147
20.

Predicting the probability of significant prostate cancer in Japanese men with serum prostate-specific antigen less than 10 ng/mL: development of a novel pre-biopsy nomogram.

Ohigashi T, Kanao K, Mizuno R, Kikuchi E, Nakashima J, Oya M.

Int J Urol. 2010 Mar;17(3):274-80. doi: 10.1111/j.1442-2042.2010.02453.x. Epub 2010 Feb 10.

Supplemental Content

Support Center